129 related articles for article (PubMed ID: 25247668)
21. Prognostic and predictive markers for the new immunotherapies.
Mahoney KM; Atkins MB
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
[TBL] [Abstract][Full Text] [Related]
22. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
23. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
Norde WJ; Maas F; Hobo W; Korman A; Quigley M; Kester MG; Hebeda K; Falkenburg JH; Schaap N; de Witte TM; van der Voort R; Dolstra H
Cancer Res; 2011 Aug; 71(15):5111-22. PubMed ID: 21659460
[TBL] [Abstract][Full Text] [Related]
24. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
25. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors.
Rey J; Veuillen C; Vey N; Bouabdallah R; Olive D
Trends Mol Med; 2009 Jun; 15(6):275-84. PubMed ID: 19487160
[TBL] [Abstract][Full Text] [Related]
26. Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies.
Rai KR
Semin Hematol; 1999 Oct; 36(4 Suppl 5):12-7. PubMed ID: 10528911
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of follicular T-helper cells in primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma and dermatitis.
Ally MS; Prasad Hunasehally RY; Rodriguez-Justo M; Martin B; Verdolini R; Attard N; Child F; Attygalle A; Whittaker S; Morris S; Robson A
J Cutan Pathol; 2013 Dec; 40(12):1006-13. PubMed ID: 24274425
[TBL] [Abstract][Full Text] [Related]
28. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance.
Di Carlo E; D'Antuono T; Pompa P; Giuliani R; Rosini S; Stuppia L; Musiani P; Sorrentino C
Clin Cancer Res; 2009 May; 15(9):2979-87. PubMed ID: 19366834
[TBL] [Abstract][Full Text] [Related]
29. Programmed cell death 1-directed immunotherapy for enhancing T-cell function.
Araki K; Youngblood B; Ahmed R
Cold Spring Harb Symp Quant Biol; 2013; 78():239-47. PubMed ID: 25028401
[TBL] [Abstract][Full Text] [Related]
30. Role of the tumor microenvironment in mature B-cell lymphoid malignancies.
Fowler NH; Cheah CY; Gascoyne RD; Gribben J; Neelapu SS; Ghia P; Bollard C; Ansell S; Curran M; Wilson WH; O'Brien S; Grant C; Little R; Zenz T; Nastoupil LJ; Dunleavy K
Haematologica; 2016 May; 101(5):531-40. PubMed ID: 27132279
[TBL] [Abstract][Full Text] [Related]
31. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
[TBL] [Abstract][Full Text] [Related]
32. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin.
Cesarman-Maus G; Braggio E; Lome-Maldonado C; Morales-Leyte AL; Fonseca R
Thromb Res; 2014 Apr; 133(4):606-9. PubMed ID: 24491425
[TBL] [Abstract][Full Text] [Related]
33. [Anti-PD-1 antibody: basics and clinical application].
Tanaka Y; Okamura H
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
[TBL] [Abstract][Full Text] [Related]
34. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in hematologic malignancies.
Kansara RR; Speziali C
Curr Oncol; 2020 Apr; 27(Suppl 2):S124-S131. PubMed ID: 32368182
[TBL] [Abstract][Full Text] [Related]
36. The role of protein kinase C-alpha in hematologic malignancies.
Lahn M; Sundell K; Köhler G
Acta Haematol; 2006; 115(1-2):1-8. PubMed ID: 16424642
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
38. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.
Sasse S; Reddemann K; Diepstra A; Oschlies I; Schnitter A; Borchmann S; Engert A; Borchmann P; Klapper W
Haematologica; 2019 Jan; 104(1):e21-e24. PubMed ID: 30076177
[No Abstract] [Full Text] [Related]
39. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies.
Wang Z; Zhang Y; Mandal A; Zhang J; Giles FJ; Herr JC; Lim SH
Clin Cancer Res; 2004 Oct; 10(19):6544-50. PubMed ID: 15475442
[TBL] [Abstract][Full Text] [Related]
40. Role of Notch Receptors in Hematologic Malignancies.
Gragnani L; Lorini S; Marri S; Zignego AL
Cells; 2020 Dec; 10(1):. PubMed ID: 33374160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
